Skip to main content
Preeclampsia (PE)PregnancyDrugPhase 2

What this study is

The purpose of this study is to learn if giving 17-hydroxyprogesterone caproate (17 OHPC) to mothers with preeclampsia diagnosed before 34 weeks gestation improves mother and baby outcomes.

What's being tested

  • 17 OHPC

    Intervention · DRUG

    The study participant will be given 17 OHPC, 250mg IM at admission and every 7 days thereafter.

Study details

Official title
Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia-The PROGRESS Pilot Study
Sponsor
University of Mississippi Medical Center
Conditions
Pregnancy · Preeclampsia (PE)
Enrolling
60 people
Starts
2017-05-22
Est. completion
2027-01-31
Design
Open-label, non-randomized, single group, Phase 2
Record
View on ClinicalTrials.gov ↗